NAT1, which biotransforms many carcinogens, is genetically polymorphic. Thi
s polymorphism has been postulated as a mechanism for susceptibility differ
ences in cancer, possibly due to NAT1 activity differences. However, the re
lationship between NAT1 genotype and phenotype is not clear. In our study o
f 110 Japanese, the frequency of the NAT1*10 allele (0.53, 95% confidence i
nterval 0.46-0.59) was higher than others have observed in Caucasians (0,16
). From genotype frequency studies, 26.4% of the subjects belonged to the N
AT1*10/*10 genotype, 53.6% to the NAT1*4/*10 genotype and 20% to the NAT1*4
/*4 genotype. Neither NAT1*3 nor NAT1*11 genotype was seen in these subject
s. In female subjects, we found higher NAT1 activity in NAT1*4/*10 subjects
than in NAT1*4/*4 subjects (n = 49; 2.63 versus 2.16 nmol/min/mg protein).
NAT1 activity-difference between NAT1*4/*10 and NAT1*10/*10 was not statis
tically significant, Thus, not only the presence of NAT1*10 allele, but als
o other factors are suspected of increasing NAT1 activities. After full seq
uencing of 10 subjects, five individuals having the highest activities and
five individuals having the lowest activities, we found NAT1*18A and NAT1*1
8B to be in the high activity group and the low activity group, respectivel
y. The genotypes containing these variants were heterozygous, i.e. NAT1*4/*
18A and NAT1*4/*18B. Due to rare frequencies of these variants, they cannot
be considered as other effective, genetic factors on NAT1 activity. Age an
d tobacco smoking did not affect the relationship between NAT1 genotype and
phenotype. Pharmacogenetics 10:225-252 (C) 2000 Lippincott Williams & Wilk
ins.